AU2001284865A1 - Methods for diagnosing and treating dysautonomia and other dysautonomic conditions - Google Patents

Methods for diagnosing and treating dysautonomia and other dysautonomic conditions

Info

Publication number
AU2001284865A1
AU2001284865A1 AU2001284865A AU8486501A AU2001284865A1 AU 2001284865 A1 AU2001284865 A1 AU 2001284865A1 AU 2001284865 A AU2001284865 A AU 2001284865A AU 8486501 A AU8486501 A AU 8486501A AU 2001284865 A1 AU2001284865 A1 AU 2001284865A1
Authority
AU
Australia
Prior art keywords
dysautonomia
diagnosing
treating
methods
dysautonomic conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001284865A
Inventor
Joan M. Fallon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001284865A1 publication Critical patent/AU2001284865A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
AU2001284865A 2000-08-14 2001-08-14 Methods for diagnosing and treating dysautonomia and other dysautonomic conditions Abandoned AU2001284865A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22499100P 2000-08-14 2000-08-14
US60224991 2000-08-14
PCT/US2001/025343 WO2002014537A2 (en) 2000-08-14 2001-08-14 Methods for diagnosing and treating dysautonomia and other dysautonomic conditions

Publications (1)

Publication Number Publication Date
AU2001284865A1 true AU2001284865A1 (en) 2002-02-25

Family

ID=22843086

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001284865A Abandoned AU2001284865A1 (en) 2000-08-14 2001-08-14 Methods for diagnosing and treating dysautonomia and other dysautonomic conditions

Country Status (3)

Country Link
US (2) US6660831B2 (en)
AU (1) AU2001284865A1 (en)
WO (1) WO2002014537A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US7217133B2 (en) * 2002-04-04 2007-05-15 Jeanine Thomas Method for treating pervasive development disorder
PL1708690T3 (en) * 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Treatment of phenylketonuria with bh4
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
WO2006055511A2 (en) * 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8109879B2 (en) 2006-01-10 2012-02-07 Cardiac Pacemakers, Inc. Assessing autonomic activity using baroreflex analysis
US8658163B2 (en) * 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) * 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (en) * 2008-07-01 2019-10-31 Curemark Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
JP2012514604A (en) 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー Compositions and methods for the treatment or prevention of oral infection by E. coli
BRPI1007378A2 (en) 2009-01-06 2020-08-18 Curemark Llc compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces.
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
CA2815044A1 (en) 2010-11-19 2012-05-24 Curemark Llc Preparation and use of combination enzyme and gastrointestinal modulator delivery systems
EP2701733B1 (en) 2011-04-21 2019-04-03 Curemark, LLC Compounds for the treatment of neuropsychiatric disorders
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US20130224172A1 (en) 2012-01-03 2013-08-29 Curemark, Llc Methods of treating behavioral symptoms of neurological and mental disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99628A (en) 1991-10-02 2004-07-25 Yissum Res Dev Co Processes for the preparation of cyclic peptides, and pharmaceutical compositions containing them
AU683215B2 (en) 1992-06-12 1997-11-06 Albert Einstein College Of Medicine Of Yeshiva University Prevention and treatment of peripheral neuropathy
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5958875A (en) * 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
CA2190418A1 (en) 1996-11-15 1998-05-15 Zhi-Cheng Xiao Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
JP2002501616A (en) * 1997-05-19 2002-01-15 リプリゲン コーポレーション Methods to assist in differential diagnosis and treatment of autistic syndrome
US6020314A (en) 1998-08-11 2000-02-01 Milkhaus Laboratory, Inc. Methods for treatment of neurological disorders

Also Published As

Publication number Publication date
US20020037284A1 (en) 2002-03-28
US7138123B2 (en) 2006-11-21
WO2002014537A3 (en) 2002-05-10
WO2002014537A2 (en) 2002-02-21
US20040115182A1 (en) 2004-06-17
US6660831B2 (en) 2003-12-09

Similar Documents

Publication Publication Date Title
AU2001284865A1 (en) Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
AU2001268331A1 (en) Methods for diagnosing and treating thalamocortical dysrhythmia
AU2001265279A1 (en) Transactional supply chain system and method
EP1331278A4 (en) Refining agent and refining method
AU2002215125A1 (en) Well treatment method
AU3877900A (en) Compositions and methods for preventing and treating sexual dysfunctions
AU2001263516A1 (en) Glare reduction system and method
AU2001279850A1 (en) Method and arrangement for studsystem
AU5838700A (en) Method for treating and preventing finger disorders
AU2002213227A1 (en) Generalizer system and method
AU6421600A (en) Compacted-powder opposed twin-helical gears and method
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
WO2001075542A8 (en) Teamwork method and system
AU2001289123A1 (en) Compounds and methods for diagnosing and treating amyloid-related conditions
AU2001233932A1 (en) Method and composition
AU2001285172A1 (en) Enhanced electro-deposition device and method
AU2001218024A1 (en) Methods for treating and preventing alopecia
AU1792901A (en) Methods for treating and preventing diabetic complications
AU2001261513A1 (en) Composition and method for increasing testosterone levels
AUPP807799A0 (en) Polynucleotide and method
AU1755301A (en) Rollercross-type game and method thereof
AU2002239775A1 (en) Chemical-library composition and method
AU2001243297A1 (en) Method for treating or preventing depression
AU2001255252A1 (en) Gaming system and method
AU2002217915A1 (en) Compositions and methods for diagnosing or treating psoriasis